TE Tirzepatide Editorial

Provider review

Amble Tirzepatide Review

Released: · Last reviewed:

Direct answer

Amble is reviewed here against a fixed evidence checklist: advertised and all-in tirzepatide pricing, mandatory fees, dose coverage, pharmacy, clinician model and cancellation terms. No comparable tirzepatide price is on file for Amble: its plan table prices 'Compounded GLP-1' without naming the molecule (checked October 15, 2026.)

Key takeaways

  • No comparable tirzepatide price on file (checked October 15, 2026).
  • Mandatory fees recorded: No separate fee identified in cited pricing.
  • Compounding pharmacy, licence, facility type, clinicians, states, and cancellation terms are all unverified and shown as Verification Pending rather than inferred.
  • Compounded tirzepatide is not FDA approved and is not reviewed by the FDA before sale.
Current regulatory status — compounded tirzepatide. The FDA determined the tirzepatide shortage resolved on 2 October 2024 and reaffirmed it by declaratory order on 19 December 2024. Enforcement discretion for compounding ended on 18 February 2025 for 503A pharmacies and 19 March 2025 for 503B outsourcing facilities, and a federal court upheld the determination in May 2025. Federal law prohibits compounding a copy of a commercially available approved drug outside a shortage, so routine compounded tirzepatide is no longer permitted. Telehealth programs still sell compounded tirzepatide prepared for individual patients by state-licensed 503A pharmacies; FDA's September 18, 2026 warning letter to Empower Pharmacy (738238) said compounded tirzepatide and semaglutide products it reviewed “appear to be essentially copies” of the approved drugs. Prices on this site are dated first-party reads, not a finding that any product is lawful. Full timeline and sources.
Amble — verification checklist
ProviderAmble
Operating statusActive
Program typeCompounded-GLP-1-focused
Tirzepatide price (as captured)Its plan table prices 'Compounded GLP-1' without naming the molecule. (read 2026-10-15)
Normalised monthly costNo comparable price on file
Mandatory feesNo separate fee identified in cited pricing
Medication includedYes for quoted tirzepatide programs
Billing cadenceMonthly or multi-month
Compounding pharmacyVerification Pending
Pharmacy licenceVerification Pending
Facility type (503A/503B)Verification Pending
Named cliniciansVerification Pending
States servedVerification Pending
Dose coverageVerification Pending
Shipping termsVerification Pending
Cancellation policyVerification Pending
Refund policyVerification Pending
Auto-renewal termsVerification Pending
Evidence sourceOfficial provider
Source confidenceModerate
Price verified2026-10-15
Partially verified
Medical reviewers Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Released 2026-07-22
Updated
Price verified 2026-10-15
Methodology v4.1

What is the verdict on this provider?

Amble has no comparable tirzepatide price on file (Its plan table prices 'Compounded GLP-1' without naming the molecule). That is a disclosure gap, not a judgement about the service; ask for a written recurring price before paying.

What does tirzepatide actually cost at Amble?

No comparable tirzepatide price is on file for Amble: its plan table prices 'Compounded GLP-1' without naming the molecule (checked October 15, 2026.)

Source: joinamble.com. Confirm the recurring price after any first month, every mandatory fee and the price at your maintenance dose at checkout before enrolling.

What does the captured source actually state?

Amble — verbatim captured evidence, 2026-07-20
FieldText as captured from the provider's own page
Tirzepatide pricing, as publishedAbout $329 monthly; $255/mo on 3 months; $238/mo on 6 months; $235/mo on 12 months; first-order promotion may apply
Semaglutide pricing, as publishedNo current exact semaglutide public price verified in this capture
Fee structure, as publishedNo separate fee identified in cited pricing
Medication inclusion, as publishedYes for quoted tirzepatide programs
Billing cadence, as publishedMonthly or multi-month
Evidence typeCurrent advertised tirzepatide pricing
Capture caveatVerify semaglutide and exact checkout before publication.

How should the Amble pricing structure be read?

Amble publishes multi-month or prepaid options alongside any monthly rate. Committed tiers lower the advertised monthly figure but concentrate financial risk: if treatment stops early — and gastrointestinal effects end treatment for a measurable share of people — the money already paid is governed by cancellation and refund terms that are unverified here.

Source confidence for this record is recorded as Moderate, which is why the figures above are presented as captured text rather than asserted as the current price.

What has not been verified?

Verification Pending. Not verified first-party for Amble, and therefore not asserted: the compounding pharmacy identity and state licence, 503A versus 503B facility type, named prescribing clinicians, states served, dose coverage at higher doses, shipping terms, cancellation and refund policy, and auto-renewal terms. Publishing an inferred pharmacy name or an assumed cancellation policy would give a false impression of verification, so these fields stay blank until a checkout capture and licence lookup are completed.

What should you confirm before enrolling?

  • The recurring price after any introductory or first-month rate, in writing.
  • Every mandatory fee: membership, consultation, shipping, and any dose-related surcharge.
  • Which compounding pharmacy dispenses, its state licence number, and whether it is 503A or 503B.
  • What happens to the price when your dose increases.
  • The cancellation method, notice period, and whether prepaid months are refundable.
  • Whether the plan auto-renews and how to stop it.
  • That a licensed clinician reviews your intake and is reachable for side-effect questions.

What are the alternatives?

Primary source: Amble pricing page · captured 2026-07-20. Verify semaglutide and exact checkout before publication.

Pricing fields held25Pharmacy fields held04Policy fields held04VerifiedRequired for full review
Count of evidence fields held against the number this site requires before publishing a complete verdict. The gap is why most fields on this page read Verification Pending.
Data for: Amble: verification completeness
GroupVerifiedRequired for full review
Pricing fields held25
Pharmacy fields held04
Policy fields held04

Why is this provider not ranked on cost?

Price-classification test applied to this provider
TestResult for this provider
Recurring price statedYes
Medication includedYes for quoted tirzepatide programs
All mandatory fees confirmedNo
Classificationnot normalisable
Published reasonPrice stated in free text that cannot be normalised

What is Amble's status after the compounding change?

Amble was captured on 2026-07-20 advertising compounded tirzepatide. That capture predates nothing — it is recent — but the legal basis for the product it describes changed before it was taken. Compounding of tirzepatide was permitted only while the drug sat on the FDA shortage list. The shortage was declared resolved on 2 October 2024 and reaffirmed by declaratory order on 19 December 2024, and enforcement discretion ended on 18 February 2025 for 503A pharmacies and 19 March 2025 for 503B outsourcing facilities.

This site records Amble's prices with the date each was read and compares them only on a like-for-like basis (see the position table). If Amble continues to advertise compounded tirzepatide, the useful question is not whether the price is competitive but what legal basis the product is supplied under and which state-licensed pharmacy dispenses it. Neither is verified in this record.

Post-shortage position for Amble, as far as the evidence supports
QuestionPosition for AmbleHow this site treats it
Was compounded tirzepatide advertised at capture?YesRecorded with its read date
Operating status at captureActiveReported as captured; not re-verified since
Legal basis for continued compounded supplyNot disclosed in the captured sourceVerification Pending — not inferred
Dispensing pharmacy identityNot disclosedVerification Pending
Whether approved products are now offeredNot established in this recordVerification Pending — ask the provider directly

How was Amble's pricing classified?

Every provider on this site passes through the same four-part price test before it can appear in a cost ranking. The test asks whether the captured source states a recurring price, whether medication is included in that price, whether every mandatory fee is identified, and whether the figure describes the standard subcutaneous injection rather than an alternative formulation. Amble is assessed below against each part in turn.

Captured source text, verbatim. About $329 monthly; $255/mo on 3 months; $238/mo on 6 months; $235/mo on 12 months; first-order promotion may apply
The four-part price test applied to Amble
TestResult for this providerWhy it matters
A recurring price is statedYesAbout $329 monthly; $255/mo on 3 months; $238/mo on 6 months; $235/mo on 12 months; first-order promotion may apply
Medication is included in that priceYes for quoted tirzepatide programsDetermines whether the figure is the whole cost or only part of it
Every mandatory fee is identifiedNo separate fee identified in cited pricingA separate recurring membership or care fee changes the real monthly outlay
The figure describes the standard injectionnot applicableMicrodose, ODT, sublingual and troche preparations are not comparable with an injection
Classification resultnot normalisablePrice stated in free text that cannot be normalised

Amble does not pass, and the reason is specific: Price stated in free text that cannot be normalised. This is a statement about disclosure, not about service quality or value. A provider may be excellent and still publish pricing in a form that cannot be normalised — and equally, a provider that publishes a complete price may not be the right choice on any other dimension. The exclusion means only that a like-for-like cost comparison is not currently possible.

How does Amble compare with the other programs in our index?

Amble has no comparable tirzepatide price on file: Its plan table prices 'Compounded GLP-1' without naming the molecule. For reference, the 15 programs with standing all-in prices cost $1,368 to $3,640 for twelve months on their cheapest plans (median $2,568).

The standing-price index, for context (sorted low to high by twelve-month cost, November 8, 2026)
#ProgramLowest monthlyPlan behind itMonth to month12-month costHow the 12 months are boughtSource · read
1Mondae$114$114/mo on a prepaid 6-month plan ($684)$126$1,368two 6-month plans at $684mondae.com · 2026-10-15
2NexLife$115$115/mo on a 12-month plan ($1,380)$129$1,38012-month plannexlife.us · 2026-11-06
3TRYM Health$125$125/mo on the 12-month plan ($1,500 one-time payment)$180$1,50012-month one-time paymenttrymhealth.com · 2026-11-08
4Eden$129$129 every month$129$1,54812 × $129eden.health · 2026-10-15
5Sprout Health$149$149/mo on the 12-month plan ($1,788 up front)$199/4 wk$1,78812-month plan billed up frontjoinsprouthealth.com · 2026-10-15
6He & She MD$159$159/mo on the 12-month plan$339$1,90812 × $159heandshemd.com · 2026-10-15
7Bodybuilding Health+$174.67$174.67/mo on 6 months$209$2,096two 6-month plansbbhealthplus.com · 2026-10-15
8TelePep$214$214/mo on the annual plan ($2,568 up front)$249$2,568annual plan up fronttelepeptide.org · 2026-10-15
9Yucca Health$225$225/mo on 6 months ($1,350)$258$2,700two 6-month planstryyucca.com · 2026-09-04 (carried)
10Join Josie$233.25$233.25/mo on 12 months ($2,799)$349$2,79912-month planjoinjosie.com · 2026-10-15
11Pallas Health$239$239/mo average on the annual plan$299/4 wk$2,86812 × $239 averagepallashealth.co · 2026-10-15
12Fridays$240$240/mo on the annual plan (paid annually)$359$2,88012 × $240joinfridays.com · 2026-10-15
13Found$239$239 per 4 weeks on the 12-month cash plan$359/4 wk$3,10713 cycles × $239joinfound.com · 2026-10-15
14Zappy Health$299$299/mo on 6 months ($1,794)$349$3,588two 6-month planszappyhealth.com · 2026-11-08
15Enhance.MD$280$280 per 4 weeks on the 12-month plan$329/4 wk$3,64013 cycles × $280enhance.md · 2026-10-15

What else does Amble's captured record contain?

The full record held for Amble is reproduced below. This site publishes the underlying capture rather than only its own summary, so a reader can see exactly what the interpretation rests on and disagree with it if the reading looks wrong.

Complete captured record for Amble
FieldValue held for this provider
Programme categoryCompounded-GLP-1-focused
Operating statusActive
Tirzepatide pricing, as capturedAbout $329 monthly; $255/mo on 3 months; $238/mo on 6 months; $235/mo on 12 months; first-order promotion may apply
Semaglutide pricing, as capturedNo current exact semaglutide public price verified in this capture
Mandatory fees, as capturedNo separate fee identified in cited pricing
Medication inclusionYes for quoted tirzepatide programs
Billing cadenceMonthly or multi-month
Evidence typeCurrent advertised tirzepatide pricing
Capture caveatsVerify semaglutide and exact checkout before publication.
SourceOfficial provider
Source confidenceModerate
Price verified2026-07-20

Amble's semaglutide pricing is recorded because the relationship between a provider's semaglutide and tirzepatide pricing is informative on its own. Semaglutide is typically the cheaper of the two in this market, and a provider whose tirzepatide premium is unusually large or unusually small relative to its semaglutide rate is worth asking about — it can reflect different pharmacy sourcing, different dose coverage, or a promotional structure that will not persist. For Amble the captured semaglutide text reads: No current exact semaglutide public price verified in this capture

The capture for Amble is rated moderate confidence. That rating reflects genuine ambiguity in the source — typically a page that presents a starting figure without stating which dose, formulation, or commitment length it applies to, or that presents different figures on different landing pages. Moderate confidence is why the figure is reported but not ranked.

What should you ask Amble before enrolling?

These questions are selected against the specific gaps in Amble's record rather than being a generic checklist. Ask them in writing and keep the reply: a verbal assurance from a sales channel is not a contractual term, and terms are what govern a dispute.

  • What is the recurring monthly price after any introductory or first-month rate?
  • Can you provide a single all-in monthly figure in writing for the standard injection?
  • Which compounding pharmacy prepares the medication, and what is its state licence number?
  • Is that pharmacy a 503A compounder or a 503B outsourcing facility?
  • Does the price change when the dose increases to 10 mg or 15 mg?
  • What concentration is dispensed, in mg/mL, and what beyond-use date is assigned?
  • How is the plan cancelled, what notice is required, and are prepaid months refundable?
  • Does the plan auto-renew, and how is renewal stopped?
  • Which licensed clinician reviews the intake, and how are side-effect questions handled?

A provider that answers all of these in writing has demonstrated something meaningful about how it operates. A provider that will not name its compounding pharmacy before payment has also told you something, and it is worth weighing that refusal as evidence in its own right.

Why is this review shorter than the others?

Because the evidence held for Amble does not support more. Its captured pricing (Price stated in free text that cannot be normalised) cannot be reduced to a comparable recurring figure, and its pharmacy, clinician, states, dose-coverage and cancellation fields are all unverified. Writing further would mean inferring facts rather than reporting them.

This site treats a short page as the correct output in that situation. The alternative — padding a review with general commentary that would read identically for any provider — would give an impression of thoroughness the underlying evidence does not justify, and would make it harder for a reader to see which providers have actually disclosed something. The length of this page is itself a finding.

What would lengthen it. A written quotation from Amble stating a recurring all-in price for the standard injection, the dispensing pharmacy's name and state licence number, and the cancellation and refund terms. Any reader who obtains those is welcome to submit them through the corrections process, and the record will be updated with a dated note.

Current approved-product pathways: Zepbound self-pay from $299 per month at the starting dose. Full pathway comparison.

What do the technical terms on this page mean?

Definitions for the 10 technical terms this page uses, including 503A, 503B, GLP-1, auto-renewal — in the specific sense used above.

Terms used on this page
503AA pharmacy that compounds patient-specific preparations against individual prescriptions. It is licensed by a state board of pharmacy and is not subject to the same federal manufacturing requirements as a 503B facility.
503BAn outsourcing facility that may compound in larger batches without individual prescriptions. It registers with the FDA and is subject to current good manufacturing practice requirements, though registration is still not product approval.
GLP-1Glucagon-like peptide-1. An incretin hormone that slows gastric emptying, signals satiety to the brain, stimulates glucose-dependent insulin release, and suppresses inappropriate glucagon secretion.
auto-renewalA term under which a plan renews automatically unless cancelled. Combined with a notice period, it determines how much money is at risk if treatment stops.
beyond-use dateThe date after which a compounded preparation should not be used. It is assigned by the compounding pharmacy based on its own conditions, and is typically much shorter than a manufacturer expiry date derived from formal stability testing.
compoundedPrepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial.
effective monthly costThe recurring amount actually paid each month once every mandatory fee is included. It is frequently higher than the advertised medication price, which is why this site normalises before ranking.
membership feeA recurring charge separate from the medication price, common in telehealth weight programmes. It can add $40 to $80 per month and frequently reverses which provider is genuinely cheaper.
mg/mLMilligrams of drug per millilitre of liquid — the concentration. Two vials containing the same nominal dose can require different injection volumes if their concentrations differ, which is why this site does not publish volume calculations.
subcutaneousBeneath the skin. Tirzepatide is given by subcutaneous injection, usually into the abdomen, thigh, or upper arm.

Frequently asked questions

How much does tirzepatide cost at Amble?

No comparable tirzepatide price is on file for Amble: its plan table prices 'Compounded GLP-1' without naming the molecule (checked October 15, 2026.) Confirm the recurring price and every mandatory fee at checkout before enrolling.

Which pharmacy does Amble use?

Not verified. The compounding pharmacy identity, its state licence, and whether it is a 503A or 503B facility have not been confirmed first-party, so nothing is asserted.

Is Amble cheaper than other providers?

No comparable tirzepatide price is on file for Amble, so this site cannot say. Programs with standing all-in prices cost $1,368 to $3,640 for twelve months on their cheapest plans (median $2,568).

Is compounded tirzepatide FDA approved?

No. Compounded tirzepatide is not FDA approved and is not reviewed by the FDA for safety, effectiveness, or quality before sale.

Sources for this page

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Change history

Substantive changes to this page
DateChange
2026-07-22Page published with current dataset snapshot.
2026-09-04Ranked set and category median rebuilt from the 2026-09-04 dataset (7 of 29 records ranked; NexLife re-read live, Yucca Health and a program since removed from this site added). Relationship disclosure updated: NexLife is a disclosed commercial partner of the publisher; this provider's own record is unchanged.
2026-11-08Price record updated to the October 15, 2026 read; checklist, verdict, cost section, position table and FAQ answers rebuilt; dated notice added above the older capture.

Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.

What else is in this section?